Coloplast (Denmark) Top Management
COLO-B Stock | DKK 889.40 2.40 0.27% |
Coloplast employs about 14.5 K people. The company is managed by 10 executives with a total tenure of roughly 33834 years, averaging almost 3383.0 years of service per executive, having 1450.0 employees per reported executive. Analysis of Coloplast's management performance can provide insight into the company performance.
Ellen Bjurgert Insider VP Relations |
Allan Rasmussen Insider Ex Operations |
Coloplast |
Coloplast Management Team Effectiveness
The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast's management efficiency ratios could be used to measure how well Coloplast manages its routine affairs as well as how well it operates its assets and liabilities.Coloplast Workforce Comparison
Coloplast AS is number one stock in number of employees category among its peers. The total workforce of Medical Instruments & Supplies industry is currently estimated at about 104,725. Coloplast retains roughly 14,500 in number of employees claiming about 14% of all equities under Medical Instruments & Supplies industry.
The company has Profit Margin (PM) of 0.2 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.3. Coloplast AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Coloplast AS Price Series Summation is a cross summation of Coloplast price series and its benchmark/peer.
Coloplast Notable Stakeholders
A Coloplast stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Coloplast often face trade-offs trying to please all of them. Coloplast's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Coloplast's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ellen Bjurgert | VP Relations | Profile | |
Allan Rasmussen | Ex Operations | Profile | |
Alain Morvan | VP Europe | Profile | |
Nicolai Andersen | Ex Innovation | Profile | |
Thomas Barfod | Controller Director | Profile | |
Anders LonningSkovgaard | Ex CFO | Profile | |
Kristian Villumsen | Pres CEO | Profile | |
Paul Marcun | Ex Growth | Profile | |
Dennis Kaysen | Director Communications | Profile | |
Dorthe Ronnau | VP Culture | Profile |
About Coloplast Management Performance
The success or failure of an entity such as Coloplast AS often depends on how effective the management is. Coloplast management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Coloplast management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Coloplast management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Coloplast AS develops and markets intimate healthcare products and services worldwide. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast operates under Healthcare Products classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 12000 people.
Please note, the presentation of Coloplast's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Coloplast's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Coloplast's management manipulating its earnings.
Coloplast Workforce Analysis
Traditionally, organizations such as Coloplast use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Coloplast within its industry.Coloplast Manpower Efficiency
Return on Coloplast Manpower
Revenue Per Employee | 1.6M | |
Revenue Per Executive | 2.3B | |
Net Income Per Employee | 324.6K | |
Net Income Per Executive | 470.6M | |
Working Capital Per Employee | 84.7K | |
Working Capital Per Executive | 122.8M |
Complementary Tools for Coloplast Stock analysis
When running Coloplast's price analysis, check to measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |